



**HAL**  
open science

## **Immunoassay quantification of human insulin added to ternary parenteral nutrition containers: comparison of two methods**

Heloise Henry, Damien Lannoy, Nicolas Simon, David Seguy, Michele d'Herbomez, Christine Barthelemy, Bertrand Decaudin, Thierry Dine, Pascal Odou

### ► To cite this version:

Heloise Henry, Damien Lannoy, Nicolas Simon, David Seguy, Michele d'Herbomez, et al.. Immunoassay quantification of human insulin added to ternary parenteral nutrition containers: comparison of two methods. *Analytical and Bioanalytical Chemistry*, 2017, *Analytical and bioanalytical chemistry*, 409, pp.3677-3684. 10.1007/s00216-017-0311-0 . hal-02149403

**HAL Id: hal-02149403**

**<https://hal.univ-lille.fr/hal-02149403>**

Submitted on 6 Jun 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## IMMUNOASSAY QUANTIFICATION OF HUMAN INSULIN ADDED TO TERNARY PARENTERAL NUTRITION CONTAINERS: COMPARISON OF TWO METHODS

Authors: Héloïse Henry<sup>1,2</sup>, Damien Lannoy<sup>1,2</sup>, Nicolas Simon<sup>1,2</sup>, David Seguy<sup>3,4</sup>, Michèle D'Herbomez<sup>5</sup>, Christine Barthélémy<sup>1</sup>, Bertrand Décaudin<sup>1,2</sup>, Thierry Dine<sup>1</sup>, Pascal Odou<sup>1,2</sup>

1. Univ. Lille, EA 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France
2. Pharmacy Institute, CHU Lille, F-59000 Lille, France
3. University of Lille, U995 – LIRIC – Lille Inflammation Research International Center, F-59000 Lille, France
4. University Hospital of Lille, Department of Nutrition, F-59000 Lille, France
5. Immunoanalysis center, Biology and Pathology Center, CHU Lille, F-59000 Lille, France

Corresponding author:

Dr. Damien Lannoy

Faculté des Sciences Pharmaceutiques et Biologiques, EA 7365 – GRITA Laboratoire de Biopharmacie, Pharmacie Galénique et Hospitalière, 3, rue du Professeur Laguesse – B.P. 83, 59006 Lille Cedex, France.

Tel: +33 3 20 96 40 29

Fax: +33 (0)3 20 95 90 09

E-mail address: [damien.lannoy@univ-lille2.fr](mailto:damien.lannoy@univ-lille2.fr).

Acknowledgments: the authors especially want to thank Mrs Alexandra Tavernier for her extensive revision of the final manuscript.

**ABSTRACT**

**Background:** Adding insulin directly into infusion bags seems to be a useful method for controlling hyperglycemia in patients under ternary parenteral nutrition (TPN). Its efficacy is assessed by glycemic monitoring but few data are available on insulin stability in this situation. Among the various methods for quantifying insulin levels in human serum, the immunoassay ones seemed potentially appropriate for a TPN admixture containing high lipid concentrations. We sought to identify and validate which of two immunoassay methods was the better to quantify human insulin and consequently be adapted to studying its stability in a TPN admixture.

**Methods:** Two immunoassay methods to quantify recombinant human insulin were assessed in industrial TPN: an immunoradiometric assay (IRMA) and an immunoelectrochemiluminometric assay (IECMA). Validation trials for both methods were based on the accuracy profile method.

**Results:** Interference with immunometric assays due to the high lipidic content of TPN was eliminated through an improved preparation protocol using a bovine serum albumin (BSA) diluted in phosphate buffer saline (PBS). The relative total error of IECMA varied from 1.74 to 4.52% while it varied from - 0.32 to 8.37% with IRMA. Only IECMA provided an accuracy profile with a 95% confidence interval of calculated-tolerance limits falling between the chosen acceptance limits (i.e. total error  $\leq \pm 10\%$ ).

**Conclusions:** IECMA combined with a BSA dilution is a simple and semi-automatic method that provides an accurate quantification of human insulin in a TPN admixture without any interference from lipids.

**Keywords:** human insulin, parenteral nutrition solutions, immunoassay, validation, accuracy profile

## INTRODUCTION

The aim of parenteral nutrition therapy is to supplement or cover nutritional requirements via the intravenous route when both oral and enteral intakes are insufficient or contraindicated. Ternary parenteral nutrition (TPN) corresponds to an admixture providing macronutrients (glucose, amino-acids, lipids) and micronutrients (electrolytes, vitamins and trace elements). Considering the amount of glucose infused, hyperglycemia is very common during TPN in elderly and home parenteral nutrition patients, and concerns most patients in intensive care units [1,2]. Hyperglycemia in both non-critically and critically ill patients receiving TPN is known to be responsible for an increase in the risk of hospital mortality [3]. Such patients may require exogenous insulin in their TPN, but in spite of the guidelines on safe practices for parenteral nutrition provided by the American Society of Parenteral and Enteral Nutrition [4], few data concerning the stability of insulin in TPN are available [5,6].

Insulin concentration is currently measured by separative methods, such as high performance liquid chromatography coupled with UV detection [7–9] or size exclusion chromatography [10], which are not adapted to the complex TPN medium. Mass spectrometry-based methods, more sensitive but more expensive, require a complicated sample preparation (i.e. immunoextraction) and dedicated equipment [11]. Radiolabeled insulin ( $^{125}\text{I}$ -insulin) [12] is useful for studying adsorption on containers, but cannot indicate any modification in biological activity, or offer any assessment of either structural or conformational changes in insulin (from primary to quaternary structure). The presence of lipids hinders the accurate measurement of insulin concentration in all-in-one TPN admixtures regardless of the quantification method [13]. This means that other assays, capable of measuring the amount of insulin in TPN admixtures precisely, have to be carried out. Immunometric assays are routinely used today to quantify human insulin and its analogues in serum [14–16]. The

1  
2  
3 ImmunoRadioMetric Assay (IRMA) [17] and ImmunoElectroChemiluminoMetric Assay  
4 (IECMA) [18] have shown a high level of specificity for human insulin because of their  
5  
6  
7 mechanism involving anti-insulin antibodies as well as their high sensitivity.  
8

9  
10 The aim of our study was to determine the ability of such techniques to quantify insulin at low  
11  
12 concentrations in a TPN admixture, to validate them and make use of one in a stability study  
13  
14 of insulin in a TPN admixture.  
15

## 16 17 18 **MATERIALS AND METHODS** 19

### 20 *Drugs, chemicals and reagents*

21  
22 Olimel™ N7E (1.5 L bags, Baxter, Deerfield, USA) is the mixture used as TPN (containing  
23  
24 glucose, amino acid solution, with other electrolytes and lipid emulsion). Decan™ (Aguettant,  
25  
26 Lyon, France) and Cernevit™ (Baxter, Deerfield, USA) were used as additives to TPN.  
27  
28 Umuline™ rapid (100 IU/mL human insulin) was purchased from Eli-Lilly (Suresnes,  
29  
30 France). Isotonic saline serum (0.9% NaCl) was purchased from Baxter.  
31  
32

33  
34 Sodium dihydrogen phosphate monohydrate ( $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ ) and sodium phosphate dibasic  
35  
36 dodecahydrate ( $\text{Na}_2\text{HPO}_4 \cdot 12 \text{H}_2\text{O}$ ), designed for phosphate buffer saline (PBS) preparations,  
37  
38 were purchased from Cooper (Melun, France). Hydrochloric acid (HCl 25%) and  
39  
40 tris(hydroxymethyl)aminomethane (TRIS) powder were purchased from Merck Millipore  
41  
42 (Molsheim, France). Bovine serum albumin (BSA) V-fraction was purchased from  
43  
44 Euromedex (Souffelmeyersheim, France). Diluted human serum albumin (dHSA, Vialebex™  
45  
46 40 mg/mL) was purchased from LFB (Lille, France). Human gamma globulins (HGBO) were  
47  
48 purchased from Sigma Aldrich (Saint Louis, USA).  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Sample preparation*

1  
2  
3  
4  
5 Cernevit™ was reconstituted with 5 mL of 0.9% NaCl and gently shaken to obtain a  
6  
7 homogenous solution. Decan™ was then directly introduced into the TPN bag. Seals were  
8  
9 finally broken by rolling the bag onto itself to mix all nutrients of the TPN admixture. After  
10  
11 mixing, this work medium corresponded to the TPN admixture (emulsion enriched with  
12  
13 vitamins and trace elements). It could be stored at 5±3°C up to 24 hours and used for other  
14  
15 assays.  
16

17  
18 All assays were performed at a 20,000 µIU/mL (i.e. 20 IU/L) insulin concentration,  
19  
20 corresponding to the usual concentration in medical wards when insulin is added to TPN.  
21  
22 Every step was carried out with calibrated laboratory materials. Samples were taken from  
23  
24 flasks immediately after preparation without any intermediate transfer step into another  
25  
26 container.  
27  
28  
29  
30

### *Instrumentation*

31  
32  
33 Immunoreactive insulin concentration was determined by IRMA with the Bi-insulin IRMA™  
34  
35 set (Cisbio international, Paris, France) or by IECMA with the Insulin Elecsys™ assay  
36  
37 (Roche diagnostics, Meylan, France). As calibration and measuring ranges were respectively  
38  
39 1 to 500 µIU/ml for Bi-insulin IRMA™ and 0.2 to 1000 µIU/ml for Insulin Elecsys™, a two-  
40  
41 step 1/200 dilution of all samples was performed. Final samples were analyzed on two  
42  
43 different instruments: radioactivity was determined on a Wizard 1470 Gamma couler  
44  
45 (CisBio, Saclay, France), while IECMA used an e601 Cobas (Roche diagnostics, Mannheim,  
46  
47 Germany). The latter apparatus was calibrated with a Calset insulin calibrating kit and  
48  
49 controlled with Precicontrol multimarker solutions both purchased from the same  
50  
51 manufacturer (Roche, Mannheim, Germany). All assays were performed in glass containers  
52  
53 (volumetric flasks or tubes) to avoid container–content interactions.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The values are given in counts per minute (CPM) for IRMA and in  $\mu\text{IU/mL}$  for IECMA. For  
4  
5 all samples, IRMA values were converted into their corresponding  $\mu\text{IU/mL}$  concentrations  
6  
7 basing calculations on a 4-parameter calibration curve (obtained by spline function or  
8  
9 Rodbard equation [19]), which had previously been fed into the FiaCalc<sup>TM</sup> software provided  
10  
11 with the gamma couler.  
12  
13

### 14 15 16 *Matrix effect*

17  
18 As explained below, with immunoassays, quantification can be made at very low  
19  
20 concentrations, thus a two-step 1/200 sample dilution was required. Both dilution steps were  
21  
22 performed in hemolysis glass tubes using a diluent with an insignificant matrix effect (tested  
23  
24 with both methods). Different types of diluents were selected and tested after a review of the  
25  
26 literature with regard to immunoassays and information on the composition of calibration  
27  
28 standards contained in commercial kits, provided by the user manuals of both methods. Both  
29  
30 dHSA and BSA, at a concentration range of 5 to 80 g/L, were diluted in 0.9% NaCl, 0.04 M  
31  
32 phosphate buffer [20], 0.04 M phosphate buffer enriched with HGBO [20], or 0.1 M TRIS  
33  
34 buffer (prepared according to the French Pharmacopoeia 11<sup>th</sup> edition). The tested  
35  
36 concentrations were 5, 10, 15, 20, 25, 30, 35, 40 g/L for dHSA and 5, 10, 20, 30, 40, 50, 60,  
37  
38 70, 80 g/L for BSA. All buffers were previously adjusted to pH 7.53 with HCl. Diluent was  
39  
40 prepared as follows: BSA or dHSA was first added into the chosen volume of 0.9% NaCl or  
41  
42 buffer and then gently shaken (to avoid foam generation) until total dissolution.  
43  
44 Measurements of all diluents were made in triplicate immediately after preparation with both  
45  
46 immunometric methods following user manual instructions to determine which diluent could  
47  
48 be used without any matrix effect. Results are presented as means of the three values.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Preparation of calibration standards and quality control samples*

To validate the assay, the preparation of calibration standard (CS) and quality control (QC) samples was performed according to the accuracy profile method. Five CS ranging from 5,000 to 40,000 IU/mL (i.e. 5, 10, 20, 30 and 40 IU/L) and four QC concentrations (7.5, 15, 25 and 35 IU/L) were prepared for imprecision and linearity studies. All samples were treated identically. CS and QC were freshly prepared by spiking the TPN admixture with volumes of insulin solution (fig 1). The same preparation protocol was used for both methods.

### *Method validation*

Validation of both methods was obtained through the accuracy profile method. Theoretical aspects of the accuracy profile are detailed by Hubert et al. [21] in the French Society of Pharmaceutical Sciences and Techniques guidelines and by Cofrac (French National Accreditation body) in the accreditation technical guide in human health SH-GTA-04 [22] to certify assays in medical biology.

Accuracy, called “total error”, corresponds to the addition of systematic error (trueness) and random error (precision) obtained with QC. Each day, a blank sample (described below), five calibration standards and four QCs, prepared in triplicate were analyzed. Finally, the accuracy profile was computed at a type I risk of 5%, with acceptance limits of  $\pm 10\%$ , even though immunoassay techniques are usually validated at  $\pm 20\%$  [23]. Trueness is represented by relative error and precision as estimated by the expectation tolerance limits (or tolerance interval), which were established through a Student t-test ( $\beta = 95\%$ ).

In order to evaluate the matrix effect on immunometric reactions, blank samples (treated with the same sample preparation protocol described previously) were measured ten times with both IRMA and IECMA. The objective was to confirm the absence of any signals signifying the absence of a matrix effect linked to the TPN admixture. These blank samples were also



essential in calculating limits of detection (LOD) and quantification (LOQ) which were established for both methods, following the International Conference on Harmonization (ICH) recommendations, from the standard derivation of 10 blank values obtained with the work medium (named  $s_b$ ), as shown in Eq (1) and (2).

$$\text{LOD} = 3.3 \times s_b / \text{slope} \quad \text{Eq (1)}$$

$$\text{LOQ} = 10 \times s_b / \text{slope} \quad \text{Eq (2)}$$

Another method described in the Cofrac technical guidelines for accreditation [22] consists in defining LOQ and LOD with the signal/noise (S/N) ratio with values from the repetition of 30 blank samples. In that case:

$$\text{LOD} = 3 \times \text{S/N} \quad \text{Eq (3)}$$

$$\text{LOQ} = 10 \times \text{S/N} \quad \text{Eq (4)}$$

All statistics and computations were obtained using Excel software (Microsoft® Office suite v2010).

To reinforce the comparison between the two methods, an analysis of variance (ANOVA) was performed, using XLSTAT (Addinsoft®, Paris, France).

## RESULTS

### *Matrix effect*

Results obtained with the various diluents for the matrix effect study are reported in table 1.

- IRMA

The matrix effect in TRIS buffer was considerable (above 5.7  $\mu\text{IU/mL}$ ) whatever the dHSA concentrations tested. BSA solution in 0.9% NaCl also yielded a strong matrix effect (which actually reached a maximum of 5.37  $\mu\text{IU/mL}$  for the highest BSA concentration) for all tested

1  
2  
3 concentrations. The diluent giving the weakest matrix effect seemed to be BSA diluted in  
4  
5 PBS at 40 g/L, which was then chosen as diluent for the IRMA method.  
6  
7

8  
9  
10 • IECMA

11 Whatever the nature of serum albumin, its concentration range or dissolution medium, the  
12  
13 matrix effect obtained by IECMA never reached zero value. Indeed, when the value obtained  
14  
15 was <LOD, the data software did not provide concentration data. All values were close to the  
16  
17 0.2  $\mu$ IU/mL LOD value. As with the IRMA method, BSA in PBS at 40 g/L showed a weak  
18  
19 matrix effect. This diluent was again chosen for the IECMA quantification method.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1: Summary of all the data points collected for the analysis. The table is organized into columns for the different variables and rows for the different data points. The table is organized into columns for the different variables and rows for the different data points.

Variable	Value	Unit	Category	Sub-category	Notes
Age	25	Years	Demographic	Age Group	Young Adult
Gender	Male	Gender	Demographic	Gender	Male
Income	50000	USD	Economic	Income Level	Mid-range
Education	High School	Education Level	Demographic	Education	High School
Occupation	Software Engineer	Occupation	Professional	Occupation	Software Engineer
Marital Status	Single	Marital Status	Demographic	Marital Status	Single
Religion	Christianity	Religion	Demographic	Religion	Christianity
Political Affiliation	Democrat	Political Affiliation	Demographic	Political Affiliation	Democrat
Health Status	Good	Health Status	Health	Health Status	Good
Smoking Status	Non-smoker	Smoking Status	Health	Smoking Status	Non-smoker
Alcohol Consumption	Occasional	Alcohol Consumption	Health	Alcohol Consumption	Occasional
Exercise Frequency	Regular	Exercise Frequency	Health	Exercise Frequency	Regular
Dietary Habits	Vegetarian	Dietary Habits	Health	Dietary Habits	Vegetarian
Stress Levels	Low	Stress Levels	Health	Stress Levels	Low
Sleep Patterns	Regular	Sleep Patterns	Health	Sleep Patterns	Regular
Mental Health	Stable	Mental Health	Health	Mental Health	Stable
Substance Use	None	Substance Use	Health	Substance Use	None
Genetic Predisposition	Low	Genetic Predisposition	Health	Genetic Predisposition	Low
Environmental Factors	Low	Environmental Factors	Health	Environmental Factors	Low
Lifestyle Choices	Healthy	Lifestyle Choices	Health	Lifestyle Choices	Healthy
Family History	None	Family History	Health	Family History	None
Medical History	None	Medical History	Health	Medical History	None
Current Medications	None	Current Medications	Health	Current Medications	None
Chronic Conditions	None	Chronic Conditions	Health	Chronic Conditions	None
Acute Conditions	None	Acute Conditions	Health	Acute Conditions	None
Genetic Testing Results	None	Genetic Testing Results	Health	Genetic Testing Results	None
Immunization Status	Up-to-date	Immunization Status	Health	Immunization Status	Up-to-date
Vaccination History	Complete	Vaccination History	Health	Vaccination History	Complete
Antibody Levels	High	Antibody Levels	Health	Antibody Levels	High
Genetic Markers	None	Genetic Markers	Health	Genetic Markers	None
Environmental Exposures	Low	Environmental Exposures	Health	Environmental Exposures	Low
Lifestyle Factors	Healthy	Lifestyle Factors	Health	Lifestyle Factors	Healthy
Family History	None	Family History	Health	Family History	None
Medical History	None	Medical History	Health	Medical History	None
Current Medications	None	Current Medications	Health	Current Medications	None
Chronic Conditions	None	Chronic Conditions	Health	Chronic Conditions	None
Acute Conditions	None	Acute Conditions	Health	Acute Conditions	None
Genetic Testing Results	None	Genetic Testing Results	Health	Genetic Testing Results	None
Immunization Status	Up-to-date	Immunization Status	Health	Immunization Status	Up-to-date
Vaccination History	Complete	Vaccination History	Health	Vaccination History	Complete
Antibody Levels	High	Antibody Levels	Health	Antibody Levels	High
Genetic Markers	None	Genetic Markers	Health	Genetic Markers	None
Environmental Exposures	Low	Environmental Exposures	Health	Environmental Exposures	Low
Lifestyle Factors	Healthy	Lifestyle Factors	Health	Lifestyle Factors	Healthy

### *Method validation*

Calculations were made with experimental values provided by automated appliances after calibrations steps. Validation trials were carried out with the accuracy profile method. Both IRMA and IECMA methods showed linearity with a calculated  $r^2 > 0.99$  relationship between theoretical and back-calculated concentrations over the whole concentration range (with p values  $< 0.0001$  obtained by ANOVA analysis). Results are presented in tables 2 and 3.

- IRMA

Limits of detection or quantification calculated with results of the IRMA method are detailed in table 2. The within-day precision (i.e. repeatability) for human insulin in TPN is less than 5.2% and between-day precision (i.e. intermediate precision) is less than 28.51% (table 3). As shown in figure 2a, the accuracy profile was not validated within the acceptance limits of  $\pm 10\%$  for the defined concentration range.

- IECMA

Both LOD and LOQ obtained with the IECMA method are presented in table 2. The within-day precision did not exceed 2.46% and the between-day precision was below 7.98% (table 3). The accuracy profile (figure 2b) was validated at 95% with an acceptance limit of  $\pm 10\%$  of the nominal value for the concentration range indicated in table 2.

Notes: 1. Registration information and details of accounts (ID) and passwords (ID) are not included in this report.  
2. All data are subject to the accuracy of the source system. Account (ID) and password (ID) are included in this report.  
3. All data are subject to the accuracy of the source system. Account (ID) and password (ID) are included in this report.

Account ID	Account Name	ID	Account ID	Account Name	ID	Account ID	Account Name

VIEW

**Table 3: Precision parameters of both methods.** Both intra-day (within-day) and inter-day (between-day) precisions for quality controls are determined with relative standard deviation (%RSD).

Quantification method	Insulin concentrations (IU/L)	Within-day precision (n=3) (%RSD)	Between-day precision (n=9) (%RSD)
IRMA	7.5	3.45	4.57
	15	2.68	5.94
	25	5.20	28.51
	35	3.43	18.79
IECMA	7.5	2.16	2.51
	15	1.49	2.27
	25	2.46	7.98
	35	1.21	3.32

## DISCUSSION

Our results show that IECMA is more precise than IRMA in measuring human insulin concentration in TPN. To our knowledge, this is the first time that a chemiluminescent method (IECMA) has been proved capable of establishing this quantification in a TPN complex medium.

Several studies measuring insulin in TPN bags have previously been performed. The techniques used were either gamma counting of added  $I^{125}$  radiolabeled insulin [12] or radioimmunoanalysis (RIA) [5,6,24,25]. However, these techniques have different negative aspects. First, gamma counting is based on radiolabeled insulin whose ternary and/or quaternary structure can be modified by labeling, which means it does not reflect the real behavior of insulin in the environment. Secondly, RIA, which uses polyclonal antibodies, has a lower specificity than the IRMA or IECMA techniques, which use monoclonal antibodies [26]. Moreover, as regards the quantification of insulin in human serum, IECMA showed a lower LOQ, a larger dynamic analysis range without dilution and closer concordance during the reanalysis of a chosen sample, compared to RIA [19]. This explains why, in our case, IRMA failed to yield a precise quantification of insulin in TPN. The advantage of our technique is that it was validated in a complete TPN medium containing various different chemical species (dextrose, amino acids and lipids enriched with vitamins and trace elements) while previous studies have not been validated in such an environment. The disadvantage of the only study which has so far used ternary parenteral nutrition [5] was to quantify insulin recovery from a TPN admixture contained in PVC or EVA bags at the end of the infusion line but his work did not target the stability of insulin with only a TPN admixture and container. Insulin quantification during storage in a TPN EVA bag has been studied but only in water [9] and aimed at illustrating adsorption on the EVA material of the bag, but not the influence of the TPN admixture.

1  
2  
3 Various commercial kits based on immunometric methods are available on the market. The  
4  
5 two methods compared in this study have been widely used over the last decade for insulin  
6  
7 quantification in human serum. Interferences are one of the most notorious issues when using  
8  
9 immunometric methods [13,26]. Insulin quantification is complicated in such a complex  
10  
11 medium as TPN because of elements that can provoke disturbance between antibodies and  
12  
13 their specific epitope. As previously described in the literature [27], additives contained in  
14  
15 marketed insulin solutions and as supplements to the TPN medium can influence the stability  
16  
17 of insulin in the same way as the very nature of the components of the TPN admixture can. It  
18  
19 was therefore essential to perform this validation study in a precisely defined TPN medium.  
20  
21 Immunometric assays seem to be by far the best analytical methods for quantifying insulin in  
22  
23 marketed solutions. Recognition of the protein by anti-insulin antibodies should prevent  
24  
25 interaction with additives such as m-cresol, because of the fundamental difference between  
26  
27 the structures of insulin and m-cresol. Solutions of m-cresol and glycerol were tested with  
28  
29 both methods to mimic the main excipients of commercially available insulins but  
30  
31 interferences caused by these two molecules have been excluded since the signal values  
32  
33 observed by both IRMA and IECMA were negligible (data not shown). The technical  
34  
35 guidelines for the accreditation of validation methods in medical biology [22], published by  
36  
37 Cofrac (French National Accreditation body) are clear enough as regards the use of  
38  
39 commercially available kits. In the present study, the matrix of interest differs from human  
40  
41 serum so it was necessary to make an extensive characterization of the chosen method to be  
42  
43 able to quantify insulin in a TPN admixture. The main inconvenience was the existence of a  
44  
45 matrix effect (mainly due to the presence of lipids that can be responsible for non-specific  
46  
47 interference). Some solutions exist to limit the impact of the lipidic emulsion: use of  
48  
49 Lipoclear<sup>TM</sup> (a non ionic polymer intended for sample clarification [28]), solid phase  
50  
51 extraction (SPE) or sample dilution. Lipoclear<sup>TM</sup> and SPE were eliminated because of  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 insufficient knowledge of their impact on the structure of insulin. The diluting of initial  
4  
5 samples was therefore selected. However, the extent of insulin immunoreactivity with  
6  
7 immunometric methods can depend on the diluent used. All calibrators sold in commercial  
8  
9 kits (whatever the chosen method) contain a BSA matrix (with unknown concentration) in a  
10  
11 buffered solution: TRIS buffer for IRMA and 2-(*N*-morpholino)ethanesulfonic acid buffer for  
12  
13 IECMA. After testing various diluents for both methods, all the measurements were finally  
14  
15 completed after sample dilutions in 4% BSA in PBS (pH 7.5) which yielded negligible results  
16  
17 for both the IRMA and IECMA methods. Despite these non-zero values and considering that  
18  
19 LOQ corresponds to about 3.3xLOD, none of the values obtained in the LOD to LOQ range  
20  
21 could be clearly distinguished. Both the IRMA and the IECMA kits are commercialized to  
22  
23 quantify insulin in human serum, so it seemed logical to select the diluent with the  
24  
25 composition closest to that of human serum which contains nearly 40 g/L of serum albumin.  
26  
27 Sorption of insulin on the inner side of the container is a well-known phenomenon, widely  
28  
29 described with several materials like polyvinyl chloride, polyethylene, polyurethane, or glass  
30  
31 for example. Works carried out by Livesey *et al.* [29] have already underlined the importance  
32  
33 of albumin in reducing this interaction.  
34  
35  
36  
37

38 The advantage of the dilution step was to provide the final sample concentration within the  
39  
40 calibration range of the quantification kits. After this step, it was necessary to validate the  
41  
42 methods. Accuracy profile is founded on the estimation of total errors including both  
43  
44 systematic and random errors (absolute bias and intermediate precision standard derivation  
45  
46 respectively). Its final representation corresponds to the largest measurement errors which  
47  
48 seem as relevant as an individual evaluation of performance parameters and their comparison  
49  
50 with acceptance criteria.  
51  
52

53 With this method, only IECMA was validated throughout the study. Indeed, the main  
54  
55 argument is that the upper and lower tolerance limits calculated for each level of  
56  
57  
58  
59  
60

1  
2  
3 concentration fell within the  $\pm 10\%$  acceptance boundaries we had defined as targets. These  
4  
5 tolerance levels were chosen with reference to the complexity of the TPN admixture, even  
6  
7 though some information from previous publications suggests a limit of  $\pm 20\%$  [30].  
8  
9 Manufacturers' instructions specify as validation criterion: recovery has to be between 90 and  
10  
11 110%. The IRMA and IECMA methods respect this condition. In such a complex medium,  
12  
13 LOD and LOQ values calculated with either quantification method are slightly different from  
14  
15 those given by manufacturers (40.5 IU/mL instead of 0.2 IU/mL for LOD obtained by  
16  
17 IECMA) although they are compatible with the concentration range chosen in this study.  
18  
19 Finally, IECMA reduces the workload compared with IRMA (which requires lag times and  
20  
21 protection against radioactive contamination). IECMA therefore seems preferable to IRMA  
22  
23 for quantifying human insulin in a TPN admixture, although this method is only usable in the  
24  
25 conditions presented in the Materials and Method paragraph: any change in the protocol  
26  
27 would require a new validation step. In spite of their high specificity, immunometric assays  
28  
29 can suffer from interferences and different cross-reactivities, depending on the assay (because  
30  
31 of the nature of the included antibodies) [15]. For these reasons, routine tests have to be  
32  
33 implemented, precisely following the same protocol as the validation one to ensure the  
34  
35 maximum chance of success.  
36  
37  
38

39  
40 In conclusion, the Elecsys<sup>TM</sup> IECMA method has proved to be sufficiently precise for the  
41  
42 quantification of human insulin in a TPN medium supplemented with vitamins and trace  
43  
44 elements in the concentration range of 5 to 40 IU/L.  
45  
46  
47  
48

#### 49 50 **ACKNOWLEDGMENT**

51  
52 The authors wish to thank Mrs Alexandra Tavernier, M.A. University of Glasgow, U.K.;  
53  
54 Professeur Agrégée, University of Lille, for her extensive revision of the final manuscript.  
55  
56  
57  
58  
59  
60

**CONFLICTS OF INTEREST**

The authors declare that they have no conflict of interest.



For Peer Review


## REFERENCES

1. McMahon MM, Nystrom E, Braunschweig C, Miles J, Compher C, American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors, et al. A.S.P.E.N. clinical guidelines: nutrition support of adult patients with hyperglycemia. *JPEN J. Parenter. Enteral Nutr.* 2013;37:23–36.
2. Edakkanambeth Varayil J, Yadav S, Miles JM, Okano A, Kelly DG, Hurt RT, et al. Hyperglycemia During Home Parenteral Nutrition Administration in Patients Without Diabetes. *JPEN J. Parenter. Enteral Nutr.* 2015;
3. Oliveira G, Tapia MJ, Ocón J, Cabrejas-Gómez C, Ballesteros-Pomar MD, Vidal-Casariago A, et al. Parenteral nutrition-associated hyperglycemia in non-critically ill inpatients increases the risk of in-hospital mortality (multicenter study). *Diabetes Care.* 2013;36:1061–6.
4. Mirtallo J, Canada T, Johnson D, Kumpf V, Petersen C, Sacks G, et al. Safe Practices for Parenteral Nutrition. *J. Parenter. Enter. Nutr.* 2004;28:S39–S70.
5. Bassons T, Maria Sanchez J, Bassas L, Cardona D, Ordonez J, Bonal J. Insulina recuperada según los componentes de la nutrición parenteral. *Rev. SENPE.* 1985;4:93–9.
6. Rusavý Z, Sramek V, Suchat R, Lacigova S, Topolcan O. Effects of carrier solution on insulin bioavailability. *JPEN J. Parenter. Enteral Nutr.* 2004;28:439–41.
7. Yilmaz B, Kadioglu Y, Capoglu I. Determination of insulin in humans with insulin-dependent diabetes mellitus patients by HPLC with diode array detection. *J. Chromatogr. Sci.* 2012;50:586–90.
8. Hoyer GL, Nolan PE, LeDoux JH, Moore LA. Selective stability-indicating high-performance liquid chromatographic assay for recombinant human regular insulin. *J. Chromatogr. A.* 1995;699:383–8.
9. Yu K-H, Tsao H-L, Lin S-J, Chen C-Y. Quantitative analysis of insulin in total parenteral nutrition bag in Taiwan. *J. Food Drug Anal.* 2016;24:214–9.
10. Oliva A, Fariña J, Llabrés M. Development of two high-performance liquid chromatographic methods for the analysis and characterization of insulin and its degradation products in pharmaceutical preparations. *J. Chromatogr. B. Biomed. Sci. App.* 2000;749:25–34.
11. Hess C, Thomas A, Thevis M, Stratmann B, Quester W, Tschoepe D, et al. Simultaneous determination and validated quantification of human insulin and its synthetic analogues in human blood serum by immunoaffinity purification and liquid chromatography-mass spectrometry. *Anal. Bioanal. Chem.* 2012;404:1813–22.
12. Marcuard SP, Dunham B, Hobbs A, Caro JF. Availability of insulin from total parenteral nutrition solutions. *JPEN J. Parenter. Enteral Nutr.* 1990;14:262–4.
13. Martínez-Subiela S, Cerón JJ. Effects of hemolysis, lipemia, hyperbilirubinemia, and anticoagulants in canine C-reactive protein, serum amyloid A, and ceruloplasmin assays. *Can. Vet. J.* 2005;46:625–9.
14. Owen WE, Roberts WL. Cross-reactivity of three recombinant insulin analogs with five commercial insulin immunoassays. *Clin. Chem.* 2004;50:257–9.
15. Heurtault B, Reix N, Meyer N, Gasser F, Wendling M-J, Ratomponirina C, et al. Extensive study of human insulin immunoassays: promises and pitfalls for insulin analogue detection and quantification. *Clin. Chem. Lab. Med.* 2014;52:355–62.
16. Manley SE, Stratton IM, Clark PM, Luzio SD. Comparison of 11 Human Insulin Assays: Implications for Clinical Investigation and Research. *Clin. Chem.* 2007;53:922–32.
17. Agin A, Jeandidier N, Gasser F, Grucker D, Sapin R. Use of insulin immunoassays in clinical studies involving rapid-acting insulin analogues: Bi-insulin IRMA preliminary assessment. *Clin. Chem. Lab. Med.* 2006;44:1379–82.
18. Sapin R, Le Galudec V, Gasser F, Pinget M, Grucker D. Elecsys insulin assay: free insulin

- determination and the absence of cross-reactivity with insulin lispro. *Clin. Chem.* 2001;47:602–5.
19. Cassidy JP, Luzio SD, Marino MT, Baughman RA. Quantification of human serum insulin concentrations in clinical pharmacokinetic or bioequivalence studies: what defines the “best method”? *Clin. Chem. Lab. Med.* 2012;50:663–6.
20. Levy-Marchal C, Bridel MP, Sodoyez-Goffaux F, Koch M, Tichet J, Czernichow P, et al. Superiority of radiobinding assay over ELISA for detection of IAAs in newly diagnosed type I diabetic children. *Diabetes Care.* 1991;14:61–3.
21. Hubert P, Nguyen-Huu J-J, Boulanger B, Chapuzet E, Chiap P, Cohen N, et al. Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal--part II. *J. Pharm. Biomed. Anal.* 2007;45:70–81.
22. COFRAC. SH GTA 04 Guide technique d'accréditation de vérification (portée A)/validation (portée B) des méthodes en biologie médicale [Internet]. 2011 [cited 2017 Jan 10]. Available from: <https://www.cofrac.fr/documentation/SH-GTA-04>
23. Kelley M, DeSilva B. Key elements of bioanalytical method validation for macromolecules. *AAPS J.* 2007;9:E156–163.
24. Christianson MA, Schwartz MW, Suzuki N. Determinants of insulin availability in parenteral nutrition solutions. *JPEN J. Parenter. Enteral Nutr.* 2006;30:6–9.
25. Ciszewska M, Knyt A, Kopec B, Pertkiewicz M. Insulin availability from all in one and fat-free nutrients admixtures. *Clin. Nutr.* 1994;13, Supplement 1:56.
26. Sapin R. [Interferences in immunoassays: Mechanisms and outcomes in endocrinology]. *Ann. Endocrinol.* 2008;69:415–25.
27. Ichikawa E, Kimura M, Mori H, Yamazaki F, Hirano K. Apparent increase of insulin peak area in HPLC analysis of a preparation consisting of a mixture of insulin and total parenteral nutrition. *Chem. Pharm. Bull. (Tokyo).* 2006;54:1196–9.
28. Saracevic A, Nikolac N, Simundic A-M. The evaluation and comparison of consecutive high speed centrifugation and LipoClear® reagent for lipemia removal. *Clin. Biochem.* 2014;47:309–14.
29. Livesey JH, Donald RA. Prevention of adsorption losses during radioimmunoassay of polypeptide hormones: effectiveness of albumins, gelatin, caseins, Tween 20 and plasma. *Clin. Chim. Acta Int. J. Clin. Chem.* 1982;123:193–8.
30. Andersen L, Jørgensen PN, Jensen LB, Walsh D. A new insulin immunoassay specific for the rapid-acting insulin analog, insulin aspart, suitable for bioavailability, bioequivalence, and pharmacokinetic studies. *Clin. Biochem.* 2000;33:627–33.


1  
2  
3  
4 **Fig. 1 Calibration standard and quality control preparation protocol.** CS and QC for  
5 validation of immunometric methods were freshly prepared by spiking chosen volumes of  
6 commercial human insulin solution after dilution in 0.04M phosphate buffer standard (PBS)  
7 in a TPN admixture  
8  
9  
10  
11  
12  
13  
14

15 **Fig. 2 Accuracy profiles of quantification of human insulin in a TPN admixture by**  
16 **IRMA (2a) or IECMA (2b).** The central line is the relative  bias (%), is the relative  
17 back-calculated concentration of the validation samples, plotted with regard to their target  
18 concentration.  represents the  $\beta$ -expectation tolerance limits. External straight lines  
19 are the acceptance limits set at  $\pm 10\%$   
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Calibration standard and quality control preparation protocol. CS and QC for validation of immunometric methods were freshly prepared by spiking chosen volumes of commercial human insulin solution after dilution in 0.04M phosphate buffer standard (PBS) in a TPN admixture

160x120mm (300 x 300 DPI)




Accuracy profile of quantification of human insulin in a TPN admixture by IRMA (2a). The central line is the relative bias (%), ■ is the relative back-calculated concentration of the validation samples, plotted with regard to their target concentration. Black diamond represents the  $\beta$ -expectation tolerance limits. External straight lines are the acceptance limits set at  $\pm 10\%$

94x56mm (600 x 600 DPI)

Review





Accuracy profile of quantification of human insulin in a TPN admixture by IECMA (2b). The central line is the relative bias (%), ■ is the relative back-calculated concentration of the validation samples, plotted with regard to their target concentration. Black diamond represents the  $\beta$ -expectation tolerance limits. External straight lines are the acceptance limits set at  $\pm 10\%$

102x72mm (600 x 600 DPI)